Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection? Article

Full Text via DOI: 10.1007/s40256-020-00429-7 PMID: 32737841 Web of Science: 000554436400001
International Collaboration

Cited authors

  • Sanchis-Gomar, Fabian; Lavie, Carl J.; Morin, Daniel P.; Perez-Quilis, Carme; Laukkanen, Jari A.; Perez, Marco, V


  • Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.

Publication date

  • 2020

International Standard Serial Number (ISSN)

  • 1175-3277

Start page

  • 413

End page

  • 418


  • 20


  • 5